Nasopharyngeal cancer

PSK was found to be effective in reducing the metastatic rate in a randomised study of 38 patients with stage I-IV nasopharyngeal carcinoma when used following radiotherapy with or without chemotherapy (14% vs 35%)62.

Median survival (35 months vs 25 months, p<0.043) and 5-year survival rate (28% vs. 15%, p<0.043) was significantly better in the PSK treatment group. The results suggest that PSK may be a useful therapeutic agent in the management of nasopharyngeal cancer.